Madrigal Pharmaceuticals, Inc. (MDGL) annual income statement — 23-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 |
|---|
| Sales/Revenue | 1.13B | 958.4M | 180.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7.58M | 14.8M | 144.25M | 2.62M | 743K | 0 | 0 | 173K | 1.3M |
| Revenue Growth % | 256.82% | 432.05% | - | - | - | - | - | - | - | - | - | - | - | - | -100% | -48.77% | -89.74% | 5416.06% | 251.95% | - | - | -100% | -86.73% | - |
| Cost of Goods Sold | 78.48M | 56.15M | 6.23M | 0 | 0 | 0 | 471K | 112K | 96K | 77K | 156 | 0 | 673K | 516K | 738K | 1.46M | 0 | 0 | 0 | 0 | 3.65M | 0 | 3.13M | 0 |
| COGS % of Revenue | - | 5.86% | 3.46% | - | - | - | - | - | - | - | - | - | - | - | - | 19.3% | - | - | - | - | - | - | 1809.25% | - |
| Gross Profit | 1.05B | 902.25M | 173.9M | 0 | 0 | 0 | -471K | -112K | -96K | -77K | -156 | 0 | -673K | -516K | -738K | 6.12M | 0 | 0 | 0 | 0 | -3.65M | 0 | -2.96M | 1.3M |
| Gross Margin % | 93.07% | 94.14% | 96.54% | - | - | - | - | - | - | - | - | - | - | - | - | 80.7% | - | - | - | - | - | - | -1709.25% | 100% |
| Gross Profit Growth % | - | 418.84% | - | - | - | 100% | -320.54% | -16.67% | -24.68% | -49258.97% | - | 100% | -30.43% | 30.08% | -112.06% | - | - | - | - | 100% | - | 100% | -326.76% | - |
| Operating Expenses | 1.37B | 1.2B | 671.77M | 380.5M | 293.57M | 242.48M | 205.85M | 94.86M | 40.36M | 31.81M | 24.98M | 3.17M | 83.28M | 87.04M | 60.35M | 51.55M | 49.77M | 61.24M | 96.11M | 63.61M | 55.5M | 68.72M | 43.97M | 29.6M |
| OpEx % of Revenue | - | 125.45% | 372.93% | - | - | - | - | - | - | - | - | - | - | - | - | 679.75% | 336.2% | 42.46% | 3675.18% | 8560.97% | - | - | 25417.34% | 2269.79% |
| Selling, General & Admin | 914.47M | 813.83M | 435.06M | 108.15M | 48.13M | 37.32M | 21.86M | 22.65M | 14.97M | 7.67M | 9.29M | 13.39M | 15.75M | 15.7M | 11.68M | 11.55M | 11.45M | 12.65M | 14.74M | 14.93M | 8.65M | 11.28M | 7.38M | 5.26M |
| SG&A % of Revenue | - | 84.91% | 241.52% | - | - | - | - | - | - | - | - | - | - | - | - | 152.32% | 77.34% | 8.77% | 563.75% | 2009.96% | - | - | 4267.63% | 403.45% |
| Research & Development | 453.05M | 388.52M | 236.72M | 272.35M | 245.44M | 205.16M | 184.81M | 72.32M | 25.39M | 24.39M | 15.93M | 54.22M | 68.2M | 71.86M | 49.41M | 41.46M | 40.25M | 51.05M | 81.58M | 52.02M | 50.5M | 59.9M | 38.14M | 24.34M |
| R&D % of Revenue | - | 40.54% | 131.41% | - | - | - | - | - | - | - | - | - | - | - | - | 546.73% | 271.92% | 35.39% | 3119.73% | 7002.02% | - | - | 22043.93% | 1866.33% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -313.51M | -300.1M | -497.88M | -380.5M | -293.57M | -242.48M | -206.32M | -94.97M | -40.46M | -31.89M | -24.98M | -3.17M | -83.95M | -87.56M | -61.09M | -45.43M | -36.9M | 80.54M | -93.71M | -66.22M | -59.15M | -71.18M | -45.35M | -28.29M |
| Operating Margin % | -27.68% | -31.31% | -276.39% | - | - | - | - | - | - | - | - | - | - | - | - | -599.05% | -249.26% | 55.84% | -3583.48% | -8911.98% | - | - | -26211.56% | -2169.79% |
| Operating Income Growth % | - | 39.72% | -30.85% | -29.61% | -21.07% | -17.53% | -117.24% | -134.75% | -26.88% | -27.64% | -687.83% | 96.22% | 4.12% | -43.33% | -34.46% | -23.13% | -145.81% | 185.95% | -41.52% | -11.94% | 16.9% | -56.97% | -60.27% | - |
| EBITDA | -312.38M | -298.59M | -496.78M | -379.97M | -293.1M | -242.08M | -205.85M | -94.86M | -40.36M | -31.81M | -24.98M | -3.17M | -83.28M | -87.04M | -60.35M | -43.97M | -34.97M | 83M | -90.99M | -62.86M | -55.5M | -68.72M | -43.8M | -27.29M |
| EBITDA Margin % | -27.58% | -31.16% | -275.78% | - | - | - | - | - | - | - | - | - | - | - | - | -579.75% | -236.2% | 57.54% | -3479.58% | -8460.97% | - | - | -25317.34% | -2092.64% |
| EBITDA Growth % | 26.3% | 39.89% | -30.74% | -29.64% | -21.08% | -17.6% | -117% | -135.03% | -26.88% | -27.33% | -688.47% | 96.2% | 4.33% | -44.23% | -37.26% | -25.75% | -142.13% | 191.22% | -44.74% | -13.28% | 19.25% | -56.91% | -60.51% | - |
| D&A (Non-Cash Add-back) | 1.13M | 1.51M | 1.1M | 527K | 467K | 405K | 471K | 112K | 96K | 77K | 156 | 2.58K | 673K | 516K | 738K | 1.46M | 1.93M | 2.46M | 2.72M | 3.35M | 3.65M | 2.46M | 1.55M | 1.01M |
| EBIT | -288.76M | -265.98M | -451.22M | -360.92M | -291.39M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -25.18M | -3.23M | -83.95M | -87.56M | -60.94M | -45.43M | -36.9M | 79.4M | -92.13M | -63.49M | -57.27M | -68.86M | -45.93M | -28.29M |
| Net Interest Income | 8.98M | 15.05M | 31.98M | 6.87M | -1.78M | 363K | 4.33M | 11.02M | 7.67M | 558K | -1.16M | -3.61M | -2.21M | -2.63M | -1.85M | -1.95M | -569K | -216K | 1.09M | 2.72M | 1.88M | 2.32M | 995K | 0 |
| Interest Income | 36.24M | 37.36M | 46.65M | 19.58M | 2.19M | 363K | 4.33M | 11.02M | 7.67M | 558K | 48.3K | 0 | 0 | 0 | 0 | 0 | 0 | 96K | 1.58M | 2.72M | 1.88M | 2.32M | 995K | 0 |
| Interest Expense | 11.19M | 22.31M | 14.67M | 12.71M | 3.96M | 0 | 0 | 0 | 0 | 0 | 1.16M | 1.06M | 2.21M | 2.63M | 1.85M | 1.95M | 569K | 312K | 489K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.07M | 11.81M | 31.98M | 6.87M | -1.78M | 636K | 4.08M | 11.02M | 7.64M | 732K | -1.41M | -3.67M | -2.21M | -2.63M | -1.7M | -1.95M | -569K | -1.45M | 1.09M | 2.72M | 1.88M | 2.32M | -588K | 416K |
| Pretax Income | -309.44M | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -68.67M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.49M | -59.13M | -68.86M | -45.93M | -27.88M |
| Pretax Margin % | -27.32% | -30.08% | -258.64% | - | - | - | - | - | - | - | - | - | - | - | - | -624.74% | -253.1% | 54.83% | -3541.8% | -8545.76% | - | - | -26551.45% | -2137.88% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -309.44M | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -6.84M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.49M | -57.27M | -68.86M | -45.93M | -27.88M |
| Net Margin % | -27.32% | -30.08% | -258.64% | - | - | - | - | - | - | - | - | - | - | - | - | -624.74% | -253.1% | 54.83% | -3541.8% | -8545.76% | - | - | -26551.45% | -2137.88% |
| Net Income Growth % | 20.98% | 38.12% | -24.69% | -26.5% | -22.12% | -19.58% | -140.92% | -155.85% | -5.32% | -18.06% | -285.51% | 92.06% | 4.47% | -43.64% | -32.52% | -26.46% | -147.37% | 185.39% | -45.87% | -10.87% | 16.83% | -49.92% | -64.77% | - |
| Net Income (Continuing) | -309.44M | -288.28M | -465.89M | -373.63M | -295.35M | -241.85M | -202.24M | -83.95M | -32.81M | -31.15M | -26.39M | -6.84M | -86.16M | -90.19M | -62.79M | -47.38M | -37.47M | 79.09M | -92.62M | -63.49M | -57.27M | -68.86M | -45.93M | -27.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.66 | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.20 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 |
| EPS Growth % | 29.09% | 41.32% | -9.55% | -16.02% | -17.77% | -11.76% | -176.74% | -113.06% | 12.6% | 49.9% | 98.74% | -1211.43% | 31.16% | -20.25% | -5.26% | -8.16% | -140.01% | 184.5% | -40.38% | 23.97% | 16.88% | -26% | -92.52% | - |
| EPS (Basic) | - | -12.85 | -21.90 | -19.99 | -17.23 | -14.63 | -13.09 | -4.73 | -2.22 | -2.54 | -5.07 | -401.56 | -30.62 | -44.48 | -36.99 | -35.14 | -32.49 | 81.55 | -96.09 | -68.45 | -90.03 | -108.31 | -85.96 | -44.65 |
| Diluted Shares Outstanding | 29.03M | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.8M | 12.24M | 5.21M | 171.01K | 2.81M | 2.03M | 1.7M | 1.35M | 1.15M | 974.81K | 963.86K | 927.59K | 636.14K | 635.8K | 534.39K | 624.37K |
| Basic Shares Outstanding | 29.03M | 22.43M | 21.27M | 18.69M | 17.14M | 16.54M | 15.45M | 15.39M | 14.8M | 12.24M | 5.21M | 171.01K | 2.81M | 2.03M | 1.7M | 1.35M | 1.15M | 968.21K | 963.86K | 927.59K | 636.14K | 635.8K | 534.39K | 624.37K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying MDGL stock.
For fiscal year 2025, Madrigal Pharmaceuticals, Inc. (MDGL) reported total revenue of $958.4M. This represents a 73397.2% increase compared to $1.3M in 2003.
Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $288.3M for the fiscal year ending 2025.
Madrigal Pharmaceuticals, Inc. (MDGL) reported an operating income of $-300.1M, resulting in an operating profit margin of -31.3%. This margin reflects the operational efficiency of the business before interest and taxes.
Madrigal Pharmaceuticals, Inc. (MDGL) generated $902.3M in gross profit for the year, representing a gross profit margin of 94.1%. This demonstrates the company's core pricing power and production efficiency.